NEW BRUNSWICK, N.J. / Dec 07, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time)
This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
The audio webcast replay will be available approximately 48-hrs after the webcast.
| Last Trade: | US$155.17 |
| Daily Change: | -0.33 -0.21 |
| Daily Volume: | 6,589,641 |
| Market Cap: | US$373.960B |
November 22, 2024 November 19, 2024 November 14, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
